Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
As of 30 August 2018, Algeria has reported 74 confirmed cholera cases from six northern and coastal areas of the country. This is the first cholera outbreak reported in Algeria in more than 20 years.
The production of this rapid risk assessment was triggered by a report by the Czech Republic of two travelassociated cases of cholera from Zanzibar (Tanzania) and the cholera epidemics in the Horn of Africa and the Gulf of Aden.
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
This risk assessment was triggered by two cases of paralytic poliomyelitis in children, caused by circulating vaccine-derived poliovirus type 1 (cVDPV1) in Ukraine during June and July 2015.
This rapid risk assessment considers the risk to the EU of an outbreak of invasive meningococcal disease in the UK and Sweden associated with the 23rd World Scout Jamboree in Japan.
This rapid risk assessment examines the implications of the temporary recommendations for EU Member States and assesses whether the developments leading to the declaration of a PHEIC represent an increased risk of WPV importation to Member States of the European Union.